NN&I - July 2010
Renal EconomicsSubscribe to our free eNewsletter at www.nephronline.comJuly 2010 Nephrology News & Issues 31 mately $56/treatment is allocated for ESA costs. For our centers, that corresponds to about 5,000 units of Epogen per treatment. Our strategy: We have been studying protocols to keep the hemoglo-bin levels in the lower range of the targeted 10 to 12 g/dL. Considerations include weekly subcutaneous injections, weekly hemoglobin tracking, and increasing scrutiny for the appropriateness of very high ESA doses. We plan to imple-ment a formal anemia management program, where dedi-cated "anemia managers" with remote data access to our American Association of Kidney Patients Annual ConventionSeptember 2-4, 2010 Tampa, FloridaConnecting Health Care Professionals, Patients and the Community. Discover - Unite - Take ActionAMERICAN ASSOCIATION OF KIDNEY PATIENTS 37th Annual Convention Join the American Association of Kidney Patients (AAKP) Sept. 2-4, for the AAKP National Convention. This is a unique opportunity for physicians, nurses, dietitians and social workers to learn from one another as well as the patients you serve. Learn - Network and Be Inspired! Professional Registrations start at $190. Encourage your patients to attend - patient registrations start at $90. One-day registrations are also offered for health care professionals and patients. Continuing education credits are available for social workers and nurses pending approval from accrediting agencies. For more information contact AAKP at 1-800-749-2257 or visit www.aakp.org . Variable Case-Mix Adjustment Multiplier Age: 18-44 1.194 45-49 1.000 60-69 1.012 70-79 1.057 80+ 1.076 Female 1.132 Body surface area (per 0.1 m2) 1.034 Underweight (BMI < 18.5) 1.020 Duration of renal replacement therapy < 4 months 1.473 Alcohol/drug dependence 1.150 Cardiac arrest (any) 1.032 Pericarditis (duing prior 0-3 months) 1.195 HIV\\AIDS (any) 1.316 Hepatitis B (any) 1.089 Gastrointestinal bleeding (during prior 0-3 months) Septicemia 1.234 Pneumonia 1.307 Gastrointestinal bleeding (during prior 0-3 months) 1.316 Hereditary hemolytic or sickle cell anemia (any) 1.226 Cancer (since 1999) except nonmela- noma skin cancer 1.228 Myelodysplastic syndrome (any) 1.084 Monoclonal gammopthy (any) 1.021 Facility adjustment: < 3000 treatments per year 1.202Table 1. Case-mix adjustment variables for ESRD bundled payment system (from CMS 1418-P) RenalEconomics_13.indd 31 6/16/10 6:43:27 PM
You must have JavaScript enabled to view digital editions.
